



9 June 2020

Sydney, Australia

Rights Issue Close Date

Sydney, 9 June 2020: Noxopharm (ASX: NOX) reminds shareholders that the closing date for applications under its current Rights Issue Prospectus is 5.00pm (AEST) on 11 June 2020.

Please note that:

- the payment of cleared funds must be received by this time;
- the deadline can not be extended; and
- there is no shortfall or additional share facility under this Rights Issue Prospectus.

Entitlements were based on the number of Shares held as at 7.00pm (AEST) on 20 May 2020 ("Record Date") as recorded in the Company's Share Register.

The process to apply for Shares based on a holder's entitlement is outlined in Section 2.9 of the Rights Issue Prospectus dated 13 May 2020 ("Prospectus"). A copy of the prospectus can be located at:

<https://www.asx.com.au/asxpdf/20200513/pdf/44ht4z5njghcrq.pdf>

To subscribe:

1. You need to complete and submit the personalised Application Form attached to the Prospectus (together with bank confirmation of the transfer of the application monies into the Company's bank account) in accordance with the instructions on that form. A Prospectus was mailed or emailed to each eligible shareholder on 21 May 2020; or
2. Alternatively, you can pay by BPAY® or electronic funds transfer (EFT) in accordance with the instructions on the Application Form. If paying by BPAY® or EFT in accordance with the instructions on the Application Form, there is no need to submit the completed Application Form.

To download a copy of your personalised Application Form, either:

- (a) 'Login as an existing user' at the Automic Investor centre at the link below



- (b) 'Register as a new user' at the Automic Investor centre using your HIN/SRN and registered address details at the link below

<https://investor.automic.com.au/#/home>

- (c) Call the Automic Investor phone line on 1300 288 664. Please have your HIN/SRN and holder details and an email address for the Application Form to be emailed to available when calling.

Before deciding whether or not to subscribe, you should read and consider the prospectus in full, including, without limitation, the key risk factors associated with an investment in the Company outlined in the prospectus.

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda[®] and is the major shareholder in U.S. biotechnology company, Nyrada Inc. (ASX:NYR).

www.noxopharm.com

Investor & Corporate enquiries:

Prue Kelly

M: 0459 022 445

E: info@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Media enquiries:

Catherine Strong

Citadel-MAGNUS

T: 02 8234 0111

E: cstrong@citadelmagnus.com

The release of this announcement has been authorised by the Noxopharm Board of Directors

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.